| Overview |
| Management |
| Scientific advisory board |
| Publications |
| News |
| The Ubiquitin System |
| Proteologics Discovery Platfrom |
| Target Discovery and Validation |
| Assay Development |
| Drug Discovery |
| Drug Development |
| Link |
| Antiviral programs |
| Anticancer programs |
| Collaborations |
Glaxo Smith Kline LLC
On February 2010 Proteologics entered into an R&D collaboration with GSK on six drug discovery projects. The projects follow different directions for the development of novel treatment for cancer.Teva Pharmaceutical Industries Ltd.
In 2005 Proteologics entered into an R&D collaboration with Teva Pharmaceutical Industries Ltd. to promote two anti-cancer projects. The projects follow different directions for the development of novel treatment for cancer. Proudly, we have reached the deadlines in both projects. Following this in September 2008 Teva activated its right to take license to these two programs and in addition Teva also took license to a third program - the development of novel treatment for metastatic cancers.New collaborations
There is a known causative link between the ubiquitin system and many other major human diseases including cancer, neuro-degenerative conditions (such as Alzheimer's and Parkinson's diseases), metabolic disorders and viral infections. Based on Proteologics' leading position in ubiquitin based target and drug discovery, additional research programs in cancer and cardiovascular diseases are currently under discussion with potential corporate partners.
